Abstracts Archive - Page 431 of 1683 - ATC Abstracts

2020 American Transplant Congress
Characteristics of Kidney Transplant Patients Diagnosed with Histoplasmosis
C. Miles, J. Hall, S. Westphal, E. Langewisch
University of Nebraska Medical Center, Omaha, NE
*Purpose: Histoplasmosis is responsible for the greatest number of hospitalizations and deaths due to endemic mycoses in the United States. Although lying near the western…
2020 American Transplant Congress
Multi-Organ Procurement Organization Review of the Impact of Reactive Anti-HCV and HCV NAT Results
C. C. Muse, C. A. Hostetler, R. A. Squires, J. P. Orlowski
LifeShare Transplant Donor Services of Oklahoma, Oklahoma City, OK
*Purpose: Previously a single organ procurement organization (OPO) reviewed data from a 15 month cohort (1/1/2016 to 3/31/17) and concluded that donors who tested positive…
2020 American Transplant Congress
Using HCV Infected Organs and the Challenge of Third-Party Payers
R. Daloul, A. Michaels, L. Sobotka, T. Pesavento, K. Washburn
Comprhensive Transplant Center, The Ohio State University, Columbus, OH
*Purpose: The practice of transplanting organs from hepatitis C viremic donors (HCV NAT+) into negative recipients hinges on the ability to ensure direct acting antiviral…
2020 American Transplant Congress
Experiences and Challenges Faced by Organ Transplant Recipients with Donor-Derived Hepatitis C Virus Infection
K. Prakash¹, C. Ramirez-Sanchez¹, S. I. Ramirez¹, C. Logan¹, N. Law¹, K. Mekeel², V. Pretorius², S. Aslam¹
¹Medicine, University of California San Diego, San Diego, CA, ²Surgery, University of California San Diego, San Diego, CA
*Purpose: Recently, transplantation of organs from viremic donors with hepatitis C virus (HCV-V) has increased. Currently, there is a lack of standardization of consent forms…
2020 American Transplant Congress
The Clinical Impact of HCV D+/r- Kidney Transplantation
S. Meade¹, M. A. Simpson², E. D. Walshe², M. E. Akoad², F. D. Gordon²
¹Lahey Clinic, Burlington, MA, ²Transplantation, Lahey Clinic, Burlington, MA
*Purpose: Transplantation of hepatitis C (HCV) positive organs into HCV negative recipients raises concerns regarding potential for infections unresponsive to DAAs. In September 2018, we…
2020 American Transplant Congress
Infectious Complications in Elderly Kidney Transplant Recipients Undergoing Desensitization
S. Sethi, R. Najjar, A. Peng, A. Vo, S. Jordan, E. Huang
Cedars Sinai Medical Center, West Hollywood, CA
*Purpose: Data is limited on the impact of desensitization on infectious complications in elderly kidney transplant (KT) recipients. We examined infectious complications in elderly KT…
2020 American Transplant Congress
Successful Use of Tedizolid for the Treatment of Nocardiosis in Transplant Recipients
R. Odrobina¹, B. Tritle², C. A.Gomez¹
¹Division of Infectious Diseases, University of Utah, Salt Lake City, UT, ²Department of Pharmacy, University of Utah, Salt Lake City, UT
*Purpose: Nocardiosis is an opportunistic infection occasionally seen after solid organ (SOT) and hematopoietic stem-cell transplantation. Treatment is challenging due to the limited number of…
2020 American Transplant Congress
Characteristics of Early BK Viremia after Renal Transplantation at an Urban Academic Medical Center
K. Kurzweil, K. Lamartina, K. Svaflarska, D. Kutrzuba, N. Fayyaz, O. Piatek, P. West-Thielke, Z. Hajjiri, I. Tzvetanov, E. Benedetti, A. Lichvar
University of Illinois at Chicago, Chicago, IL
*Purpose: BK viremia (BKV) is a deleterious complication after renal transplantation that can compromise allograft function. Centers face the challenge of identifying at-risk patients and…
2020 American Transplant Congress
Use of Direct Acting Antiviral Medications in Transplant Recipients Receiving Organs from Hepatitis C Viremic Donors
S. Bova¹, A. Cameron¹, C. Durand¹, J. Katzianer², M. LeGrand², L. Boyer¹, J. Glorioso³, L. P. Toman¹
¹The Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins Home Care Group, Baltimore, MD, ³Thomas Jefferson Univeristy Hospital, Philadelphia, PA
*Purpose: The availability and high efficacy of direct acting antivirals (DAAs) to treat hepatitis C (HCV) is changing practice in solid organ transplant. A large…
2020 American Transplant Congress
Valganciclovir Prophylaxis is Not Associated with Polyomavirus Viremia after Renal Transplantation
D. Conti¹, D. Schuster¹, M. Garner¹, E. Maciera¹, S. Patel²
¹Albany Medical Center, Albany, NY, ²Surgery, Albany Medical Center, Albany, NY
*Purpose: Recent studies have implicated prophylactic valganciclovir (VGC) therapy after renal transplantation to be associated with an increased rate of BK polyomavirus viremia and nephropathy.…